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Abstract 
Background. The exact efficacy of pre liver transplant (LT) therapy for 
hepatocellular carcinoma (HCC) and the impact on survival after LT remain 
controversial in regard to salvage LT. 
Materials and Methods. Of 79 patients transplanted in Nagasaki University 
Hospital between August 1997 and December 2007, 29 patients (36.7%) were 
indicated for HCC based on the Milan criteria using computed tomography 
and magnetic resonance imaging. Pre-LT therapy other than liver resection 
had been performed in 18 cases (62.1%) for 24 lesions. Treated lesions were 
analyzed histologically using thin slices of the whole explanted liver.  
Results. Pre-LT therapy included transarterial chemoembolization (TACE) 
for 10 lesions, percutaneous ethanol injection (PEI)+TACE for 1 lesion, PEI 
in 6 lesions and ablation therapy in 7 lesions. Under preoperative imaging 
study, 19 lesions (79.1%) were “thought-to-be” necrotic by pre-LT therapy. 
However, histologically, viable HCCs were still observed in 9 lesions (9/19 
47%). A median interval between the first pre-therapy and LT was 22 
months, while last pre-LT therapy and LT was 11 months. No sarcomatous 
HCC or forced portal venous tumor thrombus was found in all cases with 
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residual lesions. One peritoneal recurrence has occurred after LT, in whom 
PEI and RFA had been performed before LDLT. The disease free survival 
after LDLT was comparable to that of cases without pre-LT therapy. 
Conclusion. Half of the preoperatively “thought-to-be” necrotic lesions still 
contained viable HCC cells after the pre-LT treatment. Overall, the history 
of preLT therapy does not preclude or interfere following LT, although 
percutaneous treatment may spread disseminated tumor cell growth under 
immunosuppression. 
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Introduction 
In Japan, where the availability of deceased liver donors is limited, 
hepatocellular carcinoma (HCC) is primarily either treated with hepatic 
resection, locoregional therapy and transarterial chemoembolization.1-3 
However, when HCC recurs and further treatment is no longer possible, liver 
transplantation (LT) may be considered as salvage LT. 4 
There are drawbacks of pre-LT treatment for HCC during the waiting 
period. Dissemination5 and implantation6 may occur after puncture of HCC 
and they may form tumors after the administration of immunosuppressive 
drugs. In addition, after incomplete locoregional therapy, sarcomatous 
changes have been reported.7 With subsequent liver transplantation, 
damage to vital vascular structures can occur (hepatic artery, portal vein) 
which may affect the outcome of liver transplantation. Therefore, pre-LT 
therapy for HCC may increase the possibility of unfavorable changes in HCC 
and mask the possibility of occult HCC in a background liver, thereby 
compromising the outcome of LT. Therefore, the effect of pre-LT therapy on 
HCC and the outcome of LT for HCC, especially within the Milan criteria, 
have been reported with mixed results.8-15 
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A recent paper has reported the multiple occurrence and spread of HCC 
in a cirrhotic liver using whole liver histological examination (WLHE). 
However, the exact therapeutic effect of pre-LT treatment on primary HCC 
has not been analyzed. Explant analyses using WLHE were used, since it is 
the only opportunity to investigate the true viability of HCC in thought-to-be 
completely necrotic lesions following pre-LT therapy in imaging. This study, 
investigated the accuracy of pre-LT therapy for HCC and its impact on the 
outcome of LT. 
 
Materials and methods 
Patients 
Of 79 cases transplanted in Nagasaki University Hospital before Dec. 2007, 
29 case (36.7%) were indicated for HCC within the Milan criteria and for 18 
cases (62.1%), pre-LT therapy other than liver resection was performed (Fig. 
1). WLHE was performed with dedicated pathologists, with 5-7 mm slice for 
whole liver explants. Residual HCCs after pre-LT therapy were investigated 
histologically in combination by various factors.  
This study was approved by the local Institutional Review Board and 
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written informed consent was obtained from all patients. 
 
Patient characteristics 
All patients were indicated for LDLT as “salvage LT”. The etiology in 
these cases was hepatitis C virus (HCV) infection in 12 patients and 
hepatitis B virus (HBV) in 6 patients. There were 7 females and 11 males, 
with a median age of 57 years (range, 48–61 years). The median values of 
alpha-fetoprotein (AFP) and protein-induced vitamin K antagonists II 
(PIVKA-II) were 30.25 ng/ml (range 0.8-806.1) and 23 g/ml (range, 6-247).  
 
Liver transplantation and preoperative therapy for HCC 
The median follow-up period was 24 months (range, 12-45 months). 
Pretreatment for HCC was performed prior to LT for 24 lesions in 18 
patients, which included transarterial chemolipiodolization (TACE) in 10 
lesions, radiofrequency ablation (RFA) in 7 lesions, percutaneous ethanol 
injection therapy (PEIT) in 6 lesions, TACE with PEIT in 1 lesion. Based on 
the imaging findings, all HCCs were considered to be within the Milan 
criteria. The clinical characteristics of the 18 patients are summarized in 
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Table 1.  
All lesions were surveyed by based on multidetector computed 
tomography scanning (MDCT) and magnetic resonance imaging (MRI) done 
within 1 month before transplant. Preoperatively “thought-to-be” necrotic 
lesions were not counted as HCC lesions counted for Milan criteria. Only 
“thought-to-be” viable lesions evaluated by MD-CT with contrast media and 
MRI-SPIO were counted, which is also determined by Japanese national 
health insurance system. Preoperative imaging findings showed 5 patients 
with solitary viable HCC, 5 patients with double viable HCCs, 1 patient with 
triple viable HCCs and 7 patients with no viable HCCs. All patients met the 
Milan criteria with a solitary nodule 5 cm in size or 3 nodules 3 cm for 
multi-nodular HCC. 18 
 
Whole liver histological examination (WLHE) 16 
After explanation, the cirrhotic livers were fixed in formalin for 48 hr. The 
livers were then sectioned at 5-7 mm intervals and each section was carefully 
inspected and mapped. All sections were embedded in paraffin and all slides 
were made from the paraffin-embedded material and routinely stained with 
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hematoxylin and eosin. The median total number of slides for each patient 
was 116.5 (range, 64-185 slides). All slides were examined by an experienced 
pathologist (co-authors S.O. and H.M.). The pathological diagnoses and 
analyses were made according to the fourth edition of The General Rules for 
the Clinical and Pathological Study of Primary Liver Cancer, published by 
the Liver Cancer Study Group of Japan. 17 
 
Statistical analysis 
A statistical comparison of survival after LT was performed using the 
Kaplan-Meier method and compared by the log-rank test. Results were 
considered statistically significant when the p values were less than 0.05.   
 
Results 
At the time of LDLT, there was no sign of extrahepatic cancer spread in 
any of the patients. Histologically, after pre-LT therapy, viable HCCs were 
still observed in 9 (47%) out of 19 “thought-to-be necrotic” lesions. A median 
period between the pre-therapy and LT was 22 months (range 3-58 months). 
In 3 lesions, residual HCCs were found in the area next to necrotic area (Fig. 
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3), while in 6 lesions, residual HCCs were found within the same nodule (Fig. 
4). With regard to tumor differentiation, there was no sarcomatous HCC in 
the treated residual lesions. No “forced” portal venous tumor thrombus was 
found around the remaining viable HCCs.  
After LDLT, no recurrence was found except for one peritoneal 
dissemination (1/18:5.5%) after OLT. Since the type of recurrence is unusual 
after OLT, this case report will be shown below.  
In fact, there were 3 patients transplanted for HCC beyond Milan 
Criteria in which 2 patients had undergone pre-LT therapy (Fig. 1). In one 
patient, HCC recurred in the lung 12 months after LDLT, and he underwent 
partial lung resection three times. As pre-LT treatment, he had undergone 
liver resection and multiple TACE before LDLT. Another patient died at one 
month after LDLT due to hemophagocytic syndrome.  
 
Survival after LDLT 
After LT, regardless of pre-LT therapy, patient survival and recurrence free 
survival were comparable between the groups. (Fig. 5) 
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Case report 
A patient underwent pre-LT treatments and subsequently developed 
peritoneal recurrence after LDLT.  The patient was a 62-year-old male who 
had suffered from end-staged liver cirrhosis due to hepatitis C virus infection 
and was indicated for LDLT in May, 2006. Previously he underwent a 
caudate lobe resection of the liver for HCC in 2001 and TACE for HCC in 
segment 4 and 7 in 2003. Subsequently he was treated with TACE for HCC 
in segment 4 and 7 in 2004 and PEIT for HCC in segment 7 in 2004. RFA was 
procedure of a choice for an HCC in segment 2 in January, 2006. Finally, he 
developed end-staged liver failure and underwent a transplant in May, 2006. 
In the explanted liver, under WLHE, no viable HCCs were found.  
However, following an increase in the AFP and PIVKA-II, two mass lesions 
were found in Douglas’ pouch and the left lower abdomen in October, 2007. 
He had been on cyclosporine monotherapy as immunosuppression. Two 
lumpectomies were performed, which revealed moderately differentiated 
HCC under histological examination. It was presumed that the pre LT 
treatment had disseminated the HCC, which developed slowly after the 
LDLT (Fig. 6). In August 2008, the patient died due to the multiple 
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recurrence of HCC (local recurrence in the Douglas’s pouch, bone metastasis, 
multiple liver metastases in the graft and multiple lung metastases).
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Discussion 
The present study demonstrated that after pre-LT therapy, 47% of the 
lesions still had viable HCC cells. Previously, Kim et al. 19 reported that a 
viable tumor volume ratio greater than 10% after preLT therapy was a 
significant prognostic factor. Pompili et al. 20 also reported that 58.7% of 
HCC had partial necrosis after percutaneous ablation procedures and the 
effect depended on the size of HCCs. Also, Wong et al reported that fifteen 
nodules in five patients had <75% necrosis and these were due to 
local/non-local recurrences or perhaps suboptimal treatment with RFA, 
TACE or cisplatin gel injection. 21 The mean waiting time for LT was 162.5 
days. Nine of 13 patients had a different number of nodules than before 
pre-LT therapy, although stage changed in only three patients. The last 
pre-LT therapy and LDLT, which was median 11 months in our study, 
signified that salvage LDLT was considered and performed with 1 year for 
HCC bearing patients with viral hepatitis. Indeed, the outcome of LDLT 
even after at most pre-LT therapy could bear good disease-free-survival. 
However, in the current study cohort, one case had peritoneal 
metastasis although PEI and RFA had been performed before LDLT. The 
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patient finally died 2 years after LDLT with systemic metastases following 
resection of 2 peritoneal metastases. In this case, there was no residual HCC 
in the explanted liver at the time of LDLT. This case illustrates a worst-case 
scenario with regard to pre-LT treatment for HCC. Therefore, physicians 
should keep in mind that percutaneous locoregional therapy for HCC might 
cause such micro-dissemination with subsequent growth under 
immunosuppressive therapy. The value of adjuvant chemotherapy and choice 
of immunosuppressive agent such as Rapamycin needs to be further 
determined 22. Although previous reports on pre-LT therapy basically tend to 
favor the treatment, the case documented above suggested some detrimental 
effect of percutaneous therapy for HCC. 
With regard to the recurrence-free survival after LT, there was no 
significant difference between the patients with or without pre-LT therapy. 
Recently, Yao et al. 23 reported that after downstaging with pre-LT therapy in 
61 patients the 1- and 4-year survival after LT was 96.2 and 92.1% 
respectively. There was no recurrence after LT. Overall, the recurrence-free 
survival after LT in patients after preLT treatment was as good as in 
patients with T2 HCC without therapy for HCC. The study cohort in the 
EGUCHI et al 
 14
current review were patients who received previous treatment for HCC, 
namely salvage liver transplantation. In comparison to down-staged patients, 
salvage LT patients should have a better survival since those patients have 
never demonstrated a condition beyond the Milan-Criteria. Therefore, the 
current results showing a good disease-free survival after LDLT is 
warranted. 
Since the purpose of this study is to investigate the pre-LT treated 
lesions, we did not describe too much information on untreated HCC. 
Investigation of untreated HCC and occult HCC were described by us 
recently. 16 The characteristics of the occult HCCs that were undetectable by 
imaging, included a minute (median size 6 mm), well-differentiated 
appearance (80%), with indistinct margins (85.3%) and without vascular 
invasion (94%). In the study, a multicentric occurrence of HCCs was 
demonstrated in cirrhotic livers with HCCs within the Milan criteria., 
although undetectable HCCs in cirrhotic livers may have no impact on 
recurrence after LT. 
In conclusion, after pre-OLT therapy, 47% of the lesions still had viable 
HCC cells. However, pre-LT therapy for HCC in salvage LT had no effect on 
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the outcome of LT. However, one case had peritoneal recurrence probably due 
to percutaneous locoregional therapy under immunosuppression. 
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Fig. 1. Patient demographics. LT: liver transplantation, HCC: 
hepatocellular carcinoma. 
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Fig. 2. Actual effect of pre-LT therapy on HCC 
LDLT: living donor liver transplantation, HCC: hepatocellular carcinoma 
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Fig. 3.  A case presentation.  
58 year-old male, Liver cirrhosis due to hepatitis B viral infection, 
Pre-LT imaging diagnosis: HCC 0 
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Fig. 4.  A case presentation. 
33 year-old Female, Liver cirrhosis due to hepatitis B viral infection, 
pre-LT imaging diagnosis: HCC 0  
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Fig. 5.  A case presentation of peritoneal dissemination after LDLT. 
LDLT: living donor liver transplantation. 
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Fig. 6.  Patient survival and recurrence-free survival after liver 
transplantation for patients with HCC within the Milan criteria.  
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